Treatment in Autoimmune Disease
Anokion is an innovative immune tolerance company focused on providing a more effective approach to treating autoimmune disease. Our proprietary immune tolerance platform features proteins, or antigens, that are engineered to deliver precise, targeted disease therapy, without the side effects of broad immunosuppression. Anokion’s antigen-specific platform can be translated to virtually any antigen-mediated disease, with widespread potential across multiple clinical applications.
- February 19, 2020
Anokion to Present at the 3rd Antigen Specific Immune Tolerance Summit| Read More
- January 21, 2020
Anokion Announces FDA Clearance of IND Application for its Lead Program in Celiac Disease| Read More